SCHEMBL2955559

SCHEMBL2955559

CCOc1cc(CN2CCC(N3C(=O)c4cccc(c4)C3=O)CC2)ccc1Cl

nearest known ligand 0.51

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SSTR5 P35346 8/20 0.51
KCNH2 Q12809 1/20 0.51
HRH1 P35367 2/20 0.49
HTR2B P41595 1/20 0.49
SSTR1 P30872 1/20 0.49
KDM4E B2RXH2 1/20 0.44
ALDH1A1 P00352 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
ATM Q13315 1/20 0.43
OPRM1 P35372 1/20 0.41
HTR7 P34969 1/20 0.41
DRD2 P14416 1/20 0.41
DRD4 P21917 1/20 0.41
CD274 Q9NZQ7 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1748320 0.77 SSTR5 (0.55) SSTR5KCNH2HRH1HTR2BSSTR1
SCHEMBL3787442 0.73 SSTR5 (0.67) SSTR5KCNH2HRH1HTR2BSSTR1
SCHEMBL3782537 0.73 SSTR5 (0.63) SSTR5KCNH2HRH1HTR2BSSTR1
SCHEMBL2958079 0.71 SSTR5 (0.77) SSTR5KCNH2HRH1SSTR1MEN1
SCHEMBL4047575 0.71 SSTR5 (0.48) SSTR5KCNH2HRH1HTR2BSSTR1
SCHEMBL1873099 0.71 SSTR5 (0.61) SSTR5KCNH2HRH1HTR2BSSTR1
SCHEMBL2957954 0.71 SSTR5 (0.79) SSTR5KCNH2HRH1SSTR1MEN1
SCHEMBL3098654 0.71 CTSS (0.48) SSTR5KCNH2HRH1HTR2BSSTR1
SCHEMBL3632221 0.71 SSTR5 (0.46) SSTR5KCNH2HRH1HTR2BSSTR1
SCHEMBL3634902 0.71 SSTR5 (0.67) SSTR5KCNH2HRH1HTR2BSSTR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7772253-B2 Amide derivatives as somatostatin receptor 5 antagonists HOFFMAN-LA ROCHE INC. (US) 2010-08-10 US disclosed
EP-1893603-B1 PIPERIDIN-4-YL-AMIDE DERIVATIVES AND THEIR USE AS SST RECEPTOR SUBTYPE 5 ANTAGONISTS HOFFMANN LA ROCHE (CH) 2009-10-14 EP disclosed
EP-1893603-A1 PIPERIDIN-4-YL-AMIDE DERIVATIVES AND THEIR USE AS SST RECEPTOR SUBTYPE 5 ANTAGONISTS F. Hoffmann-La Roche AG (CH) 2008-03-05 EP disclosed
WO-2006128803-A1 PIPERIDIN-4-YL-AMIDE DERIVATIVES AND THEIR USE AS SST RECEPTOR SUBTYPE 5 ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2006-12-07 WO disclosed
US-20060276508-A1 Amide derivatives as somatostatin receptor 5 antagonists F. HOFFMANN-LA ROCHE AG (CH) 2006-12-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060276508-A1 Amide derivatives as somatostatin receptor 5 antagonists SSTR5, SSTR3, SSTR1 SSTR5 1/4885KCNH2 1054/4885HRH1 212/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.